MDGL
NASDAQ HealthcareMadrigal Pharmaceuticals, Inc. - Common Stock
Biotechnology
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
๐ Market Data
| Price | $513.72 |
|---|---|
| Volume | 186,480 |
| Market Cap | 11.84B |
| Beta | -1.010 |
| RSI (14-Day) | 40.4 |
| 200-Day MA | $469.16 |
| 50-Day MA | $482.46 |
| 52-Week High | $615.00 |
| 52-Week Low | $265.00 |
| Forward P/E | 40.15 |
| Price / Book | 19.47 |
๐ฏ Investment Strategy Scores
MDGL scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Institutional Whale (75/100) โ this strategy Large-cap, institutional-quality stocks.
Lowest fit among scored strategies: ๐ Over-Hyped (16/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find MDGL in your text
Paste any article, transcript, or post โ the tool will extract MDGL and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.